Valuation: VolitionRx Limited

Market Cap 10.66M 9.35M 8.62M 8.07M 15.13M 1.01B 15.44M 104M 40.08M 497M 40.04M 39.16M 1.72B P/E 2026 *
-0.57x
P/E 2027 * -0.92x
Enterprise Value 10.66M 9.35M 8.62M 8.07M 15.13M 1.01B 15.44M 104M 40.08M 497M 40.04M 39.16M 1.72B EV / Sales 2026 *
4.3x
EV / Sales 2027 * 1.86x
Free-Float
91.38%
Yield 2026 *
-
Yield 2027 * -
1 day-0.78%
1 week-10.49%
Current month-52.06%
1 month-55.56%
3 months-67.45%
6 months-74.40%
Current year-74.96%
1 week 1.17
Extreme 1.17
1.36
1 month 1.17
Extreme 1.17
2.9
Current year 1.17
Extreme 1.17
7.73
1 year 1.17
Extreme 1.17
17.16
3 years 1.17
Extreme 1.17
31
5 years 1.17
Extreme 1.17
82.8
10 years 1.17
Extreme 1.17
136.8
Manager TitleAgeSince
Chief Executive Officer 55 06/10/2011
Director of Finance/CFO 56 01/02/2021
Chief Tech/Sci/R&D Officer 49 01/04/2024
Director TitleAgeSince
Chairman 61 06/11/2024
Director/Board Member 55 06/10/2011
Director/Board Member - 30/09/2024
Date Insider Type Main position Quantity % Market Cap.
03-17Tax

Executive/Senior Manager

5,251 0.0039%
03-17Tax

General Counsel

7,003 0.0052%
03-17Tax

Chief Technology Officer

5,310 0.0039%
Change 5-day change 1-year change 3-year change Capi.($)
-0.78%-10.49%-92.36%-95.59% 10.66M
+3.31%+12.79%+120.93%+133.91% 4.83B
+3.51%+19.57%+77.78%+205.54% 3.35B
-4.54%-2.42%-29.51%-42.93% 1.96B
+0.95%+8.70%+151.48%-42.41% 1.9B
+3.48%+10.08%+49.87%+228.62% 1.49B
+1.63%+19.62%+151.82%-50.08% 917M
-3.95%+0.72%-15.15%+34.94% 842M
-1.09%-7.70%-38.35%-20.12% 466M
-8.07%-26.89%-0.51% - 435M
Average -0.56%+3.07%+37.60%+39.10% 1.62B
Weighted average by Cap. +1.24%+9.70%+77.56%+94.22%

Financials

2026 *2027 *
Net sales 2.48M 2.17M 2M 1.87M 3.52M 234M 3.59M 24.07M 9.31M 116M 9.3M 9.1M 401M 5.73M 5.03M 4.63M 4.34M 8.13M 541M 8.3M 55.69M 21.55M 267M 21.53M 21.06M 927M
Net income -22.2M -19.47M -17.94M -16.8M -31.5M -2.09B -32.16M -216M -83.46M -1.04B -83.37M -81.55M -3.59B -19.62M -17.2M -15.86M -14.84M -27.84M -1.85B -28.41M -191M -73.74M -915M -73.67M -72.06M -3.17B
Net Debt - -
Logo VolitionRx Limited
VolitionRx Limited is a multi-national company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer, and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.
Employees
67
Date Price Change Volume
26/06/26 $1.280 -0.78% 122,605
25/06/26 $1.290 +4.88% 196,506
24/06/26 $1.230 +1.65% 163,196
23/06/26 $1.210 -9.70% 477,490
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.280USD
Average target price
16.97USD
Spread / Average Target
+1,225.47%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VNRX Stock